Delayed Regulation of GVHD with Retained GVL Effect

延迟调节 GVHD 并保留 GVL 效应

基本信息

  • 批准号:
    6922275
  • 负责人:
  • 金额:
    $ 21.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

Following allogeneic blood and marrow transplantation (BMT), the high inverse correlation between graft-versus-host disease (GVHD) and leukemic relapse necessitates that calculated measures be taken to reduce GVHD pathology while retaining a graft-versus-leukemia (GVL) effect. In this regard, we have recently found that in the MHC-matched, minor histocompatibility antigen (miHA) disparate B10.BR->CBA murine model, freshly isolated donor CD4+CD25+ T cells were effective at suppressing early-ongoing CD8+ T cell-mediated GVHD when injected as late as day 10 post-BMT. Of importance, this early regulation of developing GVHD still permitted a potent GVL effect against a host-type myeloid leukemia (MM.CBA6) challenge. The overall goal of the project outlined here is to optimize the conditions for mediating GVHD regulation while maximizing the GVL effect, and to determine the precise cellular mechanisms involved in the elimination of the leukemia cells in vivo and the requirements for regulatory cell activity in order to stop the developing GVHD response. Our working hypothesis is that donor anti-host miHA cytotoxic T lymphocytes (CTL) are generated early after transplantation and readily encounter leukemia cells before they are able to mediate extensive target cell injury of GVHD. The addition of regulatory cells at day 10 post-BMT would then suppress both the GVHD and GVL responses, but the window for GVL interaction was large enough for prior elimination of the leukemic challenge. To test this hypothesis, we will focus on the following specific aims: 1) To determine the optimum conditions and mechanism for regulatory cell control over developing GVHD responses with the longest window of interactive opportunity; 2) To determine the mechanism of the GVL activity concomitant with CD4+CD25+ T cell regulation of developing GVHD responses in the B10.BR -> CBA and B6 -> BALB.B models; and 3) To determine the effect of anti-CTLA-4 mAb and GVAX treatments on GVL activity in the context of CD4+CD25+ T cell regulation of developing GVHD.
同种异体血液和骨髓移植(BMT)后,移植物抗宿主病(GVHD)和白血病复发之间的高度负相关,需要采取计算的措施来减少GVHD病理,同时保持移植物抗白血病(GVL)的作用。在这方面,我们最近发现在mhc匹配,次要组织相容性抗原(miHA)不同的B10。BR->CBA小鼠模型,新鲜分离供体CD4+CD25+ T

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Korngold其他文献

Robert Korngold的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Korngold', 18)}}的其他基金

T cell repertoire of graft-versus-host disease and graft-versus-tumor effects
移植物抗宿主病和移植物抗肿瘤效应的 T 细胞库
  • 批准号:
    8450874
  • 财政年份:
    2003
  • 资助金额:
    $ 21.2万
  • 项目类别:
T cell repertoire of graft-versus-host disease and graft-versus-tumor effects
移植物抗宿主病和移植物抗肿瘤效应的 T 细胞库
  • 批准号:
    8242809
  • 财政年份:
    2003
  • 资助金额:
    $ 21.2万
  • 项目类别:
T cell repertoire of graft-versus-host disease and graft-versus-tumor effects
移植物抗宿主病和移植物抗肿瘤效应的 T 细胞库
  • 批准号:
    8625190
  • 财政年份:
    2003
  • 资助金额:
    $ 21.2万
  • 项目类别:
CORE--LABORATORY ANIMALS
核心——实验动物
  • 批准号:
    6658320
  • 财政年份:
    2002
  • 资助金额:
    $ 21.2万
  • 项目类别:
PRECLINICAL GVHD AND MARROW ENGRAFTMENT STUDIES
临床前 GVHD 和骨髓移植研究
  • 批准号:
    6446909
  • 财政年份:
    2001
  • 资助金额:
    $ 21.2万
  • 项目类别:
PRECLINICAL GVHD AND MARROW ENGRAFTMENT STUDIES
临床前 GVHD 和骨髓移植研究
  • 批准号:
    6300596
  • 财政年份:
    2000
  • 资助金额:
    $ 21.2万
  • 项目类别:
SYNTHETIC INHIBITORS OF CD8+T CELLS IN TRANSPLANTATION
移植中 CD8 T 细胞的合成抑制剂
  • 批准号:
    6349897
  • 财政年份:
    2000
  • 资助金额:
    $ 21.2万
  • 项目类别:
SYNTHETIC INHIBITORS OF CD8+T CELLS IN TRANSPLANTATION
移植中 CD8 T 细胞的合成抑制剂
  • 批准号:
    6698548
  • 财政年份:
    2000
  • 资助金额:
    $ 21.2万
  • 项目类别:
SYNTHETIC INHIBITORS OF CD8+T CELLS IN TRANSPLANTATION
移植中 CD8 T 细胞的合成抑制剂
  • 批准号:
    6497316
  • 财政年份:
    2000
  • 资助金额:
    $ 21.2万
  • 项目类别:
SYNTHETIC INHIBITORS OF CD8+T CELLS IN TRANSPLANTATION
移植中 CD8 T 细胞的合成抑制剂
  • 批准号:
    6046145
  • 财政年份:
    2000
  • 资助金额:
    $ 21.2万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.2万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 21.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了